Core Viewpoint - The company, China National Pharmaceutical Group Technology Co., Ltd. (08156.HK), anticipates a significant reduction in losses for the fiscal year ending June 30, 2025, projecting a loss of no more than HKD 1 million, compared to a loss of approximately HKD 19.7 million for the fiscal year ending June 30, 2024, representing a decrease of about 95% [1] Financial Performance - The expected financial improvement is attributed to several factors, including: - A year-on-year increase in gross profit of approximately HKD 9.2 million or 184% due to business improvements [1] - Enhanced cost control measures in administrative and operational expenditures [1] - Capitalized loan income of approximately HKD 3.9 million during the reporting period [1] - A reduction in financing costs resulting from loan capitalization during the reporting period [1]
国药科技股份(08156.HK)预期年度净亏不超100万港元 同比大幅收窄约95%